In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia

Diogo Gonçalves; Guylène Rignol; Pierre Dellugat; Guido Hartmann; Stephanie Sarrazy Garcia; Jeffrey Stavenhagen; Luca Santarelli; Elvire Gouze; Christian Czech

doi:10.1371/journal.pone.0244368

Loading metrics

Open Access

Peer-reviewed

Research Article

In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia

Diogo Gonçalves ,

Contributed equally to this work with: Diogo Gonçalves, Guylène Rignol

Roles Conceptualization, Formal analysis, Methodology, Visualization, Writing – original draft, Writing – review & editing

Affiliation Research and Development, Rare Disease Unit, Pfizer, Nice, France
⨯
Guylène Rignol ,

Contributed equally to this work with: Diogo Gonçalves, Guylène Rignol

Roles Conceptualization, Formal analysis, Methodology, Writing – original draft, Writing – review & editing

Affiliation Research and Development, Rare Disease Unit, Pfizer, Nice, France
⨯
Pierre Dellugat,

Roles Data curation, Formal analysis, Methodology

Affiliation Research and Development, Rare Disease Unit, Pfizer, Nice, France
⨯
Guido Hartmann,

Roles Conceptualization, Data curation, Formal analysis, Project administration, Supervision

Affiliations Research and Development, Rare Disease Unit, Pfizer, Nice, France, TOLREMO Therapeutics AG, Muttenz, Switzerland
⨯
Stephanie Sarrazy Garcia,

Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation

Affiliation Bionea, Biot, France
⨯
Jeffrey Stavenhagen,

Roles Conceptualization, Supervision

Affiliation Therini Bio, South San Francisco, CA, United States of America
⨯
Luca Santarelli,

Roles Conceptualization, Funding acquisition, Supervision

Affiliation VectivBio, Basel, Switzerland
⨯
Elvire Gouze,

Roles Conceptualization, Supervision, Writing – review & editing

Affiliation Université Côte d’Azur, CNRS, Inserm, iBV, Nice, France
⨯
Christian Czech

Roles Conceptualization, Project administration, Writing – original draft, Writing – review & editing

* E-mail: christian.czech@pfizer.com

Affiliation Research and Development, Rare Disease Unit, Pfizer, Nice, France

https://orcid.org/0000-0001-7746-0134

⨯

In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia

Diogo Gonçalves,
Guylène Rignol,
Pierre Dellugat,
Guido Hartmann,
Stephanie Sarrazy Garcia,
Jeffrey Stavenhagen,
Luca Santarelli,
Elvire Gouze,
Christian Czech

Published: December 28, 2020
https://doi.org/10.1371/journal.pone.0244368

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Achondroplasia
Is the Subject Area "Achondroplasia" applicable to this article?

Thanks for your feedback.
Fibroblast growth factor
Is the Subject Area "Fibroblast growth factor" applicable to this article?

Thanks for your feedback.
Genetically modified animals
Is the Subject Area "Genetically modified animals" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.
Heparin
Is the Subject Area "Heparin" applicable to this article?

Thanks for your feedback.
Chondrocytes
Is the Subject Area "Chondrocytes" applicable to this article?

Thanks for your feedback.
STAT signaling
Is the Subject Area "STAT signaling" applicable to this article?

Thanks for your feedback.
Point mutation
Is the Subject Area "Point mutation" applicable to this article?

Thanks for your feedback.